-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexeo Therapeutics Presents LX2006 Data Showing Sustained Cardiac Improvements in Friedreich Ataxia

PUBT·11/16/2026 12:07:47
Diffusion vocale
Lexeo Therapeutics Presents LX2006 Data Showing Sustained Cardiac Improvements in Friedreich Ataxia
  • Lexeo Therapeutics expects LX2006 pivotal trial topline data in the second half of 2027; potential accelerated-approval application targeted for first-half 2028.
  • LX2006 reduced mean left ventricular mass index 25% at 24 months in six participants with abnormal baseline readings.
  • Across 17 participants, LX2006 had no Grade 3 treatment-related serious adverse events; one possibly treatment-related Grade 2 asymptomatic myocarditis event occurred.
  • An LX2020 pivotal study is anticipated in the second half of 2027, following protocol finalization expected in the first half.
  • Cash runway extends into 2028, supporting multiple development milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.